Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection

Table 2 Univariate analysis of factors related to early recurrence

Variable	HR	95% CI	P value
Gender
Male vs. female	0.914	0.628–1.330	0.641
Age (year)	0.998	0.983–1.014	0.827
ALT (U/L)	1.148	0.726–1.816	0.799
AST (U/L)	1.138	0.760–1.704	0.527
ALP (U/L)	1.853	1.306–2.629	0.001
γ-GT (U/L)	1.613	1.135–2.291	0.008
TBIL (μmol/L)	1.229	0.813–1.858	0.325
HBV infection
Positive vs. negative	0.513	0.361–0.728	< 0.001
HBV-DNA load (IU/mL)
≥ 10³ vs. < 10³	0.591	0.373–0.934	0.023
HBV-DNA load (IU/mL)
≥ 10⁶ vs. < 10⁶	0.439	0.205–0.941	0.029
Cirrhosis
Yes vs. no	0.733	0.496–1.084	0.118
Child-Pugh class
B vs. A	0.942	0.415–2.138	0.887
Hepatolithiasis history
Yes vs. no	2.149	1.377–3.355	0.001
AFP (ng/mL)
> 20 vs. ≤ 20	0.844	0.534–1.336	0.468
CEA (μg/L)
> 10 vs. ≤ 10	2.498	1.497–4.169	< 0.001
CA19-9 (U/L)
> vs. ≤ 37	2.409	1.670–3.475	< 0.001
Tumor size (cm)
> 5 vs. ≤ 5	1.982	1.385–2.837	0.001
Tumor number
Multiple vs. single	3.110	2.080–4.650	< 0.001
Satellite
Yes vs. no	2.491	1.737–3.573	< 0.001
Macrovascular invasion
Yes vs. no	2.215	1.290–3.801	0.003
Microvascular invasion
Yes vs. no	3.035	1.629–5.656	< 0.001
Capsule integrity
Yes vs. no	0.801	0.353–1.818	0.591
E-S grade
III vs. I or II	1.468	0.995–2.167	0.053
LNM
Yes vs. no	1.591	0.943–2.686	0.082
TNM stage
III vs. II or I	1.952	1.243–3.066	0.004

Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, γ-GT γ-glutamyl transpeptidase, TBIL total bilirubin, HBV-DNA hepatitis B virus deoxyribonucleic acid, AFP alpha-fetoprotein, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, E-S Edmondson-Steiner, LNM lymph node metastasis. There were statistically significant differences for data in Italics (p < 0.05)

ISSN: 1477-7819